Moleculin Biotech, Inc.

Moleculin Biotech, Inc.verified

MBRX

Price:

$1.73

Market Cap:

$5.52M

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma mul...[Read more]

Industry

Biotechnology

IPO Date

2016-06-02

Stock Exchange

NASDAQ

Ticker

MBRX

The Enterprise Value as of December 2024 (TTM) for Moleculin Biotech, Inc. (MBRX) is -3378743.00

According to Moleculin Biotech, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -3378743.00. This represents a change of -2161.45% compared to the average of 163.90K of the last 4 quarters.

Moleculin Biotech, Inc. (MBRX) Historical Enterprise Value (quarterly & annually)

How has MBRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Moleculin Biotech, Inc. over the last ten years is 15.39M. The current -3378743.00 Enterprise Value has changed -2294.76% with respect to the historical average. Over the past ten years (40 quarters), MBRX's Enterprise Value was at its highest in in the September 2016 quarter at 60.23M. The Enterprise Value was at its lowest in in the September 2022 quarter at -19569738.70.

Quarterly (TTM)
Annual

Average

15.39M

Median

19.81M

Minimum

-20754788.80

Maximum

45.78M

Moleculin Biotech, Inc. (MBRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Moleculin Biotech, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 51.59%

Maximum Annual Enterprise Value = 45.78M

Minimum Annual Increase = -164.47%

Minimum Annual Enterprise Value = -20754788.80

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20232.47M-119.96%
2022-12373351.90-40.38%
2021-20754788.80-164.47%
202032.19M19.64%
201926.91M35.86%
201819.81M-26.16%
201726.82M51.59%
201617.70M-61.35%

Moleculin Biotech, Inc. (MBRX) Average Enterprise Value

How has MBRX Enterprise Value performed in the past?

The current Enterprise Value of Moleculin Biotech, Inc. (MBRX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-10219432.26

5-year avg

5.69M

10-year avg

15.39M

Moleculin Biotech, Inc. (MBRX) Enterprise Value vs. Peers

How is MBRX’s Enterprise Value compared to its peers?

Moleculin Biotech, Inc.’s Enterprise Value is less than Catalyst Biosciences, Inc. (1.03B), less than Pulmatrix, Inc. (10.26M), less than Cyclacel Pharmaceuticals, Inc. (-936142.00), less than Akari Therapeutics, Plc (10.29M), less than Onconova Therapeutics, Inc. (32.62M), less than Bio-Path Holdings, Inc. (4.24M), less than AN2 Therapeutics, Inc. (8.33M), less than Miromatrix Medical Inc. (90.06M), less than Inhibikase Therapeutics, Inc. (198.12M), less than PMV Pharmaceuticals, Inc. (42.60M), less than Anebulo Pharmaceuticals, Inc. (31.01M), less than Diffusion Pharmaceuticals Inc. (10.50M), less than Capricor Therapeutics, Inc. (575.76M), less than NextCure, Inc. (4.04M), less than Panbela Therapeutics, Inc. (7.83M), less than Virax Biolabs Group Limited (4.97M), greater than Allarity Therapeutics, Inc. (-12515070.00), less than ContraFect Corporation (-2858930.00), less than Avenue Therapeutics, Inc. (1.10M),

Build a custom stock screener for Moleculin Biotech, Inc. (MBRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moleculin Biotech, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Moleculin Biotech, Inc. (MBRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Moleculin Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Moleculin Biotech, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Moleculin Biotech, Inc. (MBRX)?

What is the 3-year average Enterprise Value for Moleculin Biotech, Inc. (MBRX)?

What is the 5-year average Enterprise Value for Moleculin Biotech, Inc. (MBRX)?

How does the current Enterprise Value for Moleculin Biotech, Inc. (MBRX) compare to its historical average?